JNJ-39393406

DB11867InvestigationalSmall molecule

JNJ-39393406 has been used in trials studying the treatment and basic science of DEPRESSION, Schizophrenia, Smoking Cessation, Cognition Disorders, and Alzheimer's Disease.

Mechanism: Pharmacologically active on Neuronal acetylcholine receptor subunit alpha-7
Curator reviewed
Formula / weight: C₁₉H₁₈F₂N₆O₃ · 416.389 g/mol (avg)
Code names: JNJ 39393406

Resolves to

Compound

UNIIT930SOU82PCAS953428-73-4ChEMBLCHEMBL3545291PubChem16755766

Structure

InChIKeyIURMHZBQEYNQOH-UHFFFAOYSA-NSMILESCN(C)C(=O)CCN1N=C(NC2=CC=C3OC(F)(F)OC3=C2)N=C1C1=CC=NC=C1

Targets

P36544CHRNA7

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

5Clinical trialsPhase, status and sponsor resolved per trial

4+ReferencesStructured and connected to the statements they support

Which drugs share a target with JNJ-39393406, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account